Rayner
Wade Allen has a diverse work experience in the medical industry, with a focus on sales and marketing. Wade is currently the Vice President of the Americas at Rayner, a position they have held since June 2022. Prior to this, Wade was the Director of the Americas at Rayner starting in December 2020. Wade also served as the Country Manager for USA and Canada at Rayner from January 2020.
Before joining Rayner, Wade worked at Eagle Vision, Inc. for a significant portion of their career. From September 2004 to March 2018, they held the role of Vice President of Sales and Marketing.
In 2003, Wade joined Bio-Tissue as the Director of Sales and Marketing. During their tenure, they successfully launched the company's sales and marketing organization, established a national sales team, and implemented a new branding campaign.
Wade's career at Eagle Vision, Inc. began in 1998, where they started as a Product Manager. Wade stayed in this role until July 2003.
Overall, Wade Allen brings extensive experience and expertise in sales, marketing, and management within the medical industry.
Wade Allen obtained a Bachelor's degree in History from The University of Memphis between the years 1990 and 1993.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.